

01-16-02

A

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)*(Only for new nonprovisional applications under 37 CFR 1.53(b))*Docket No.
1073.035A

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTSBox Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

BRADYKININ B1 RECEPTOR ANTAGONISTS

and invented by:

Ohlmeyer, Michael J.
Jorge Gabriel QuinteroJohn J. Baldwin
Gonghua Pan

Roland E. Dolle III

Vidyadhar Paradkar

jc821 U.S. PTO
10/046616
01/14/02If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:☒ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: PCT/US00/19185

Which is a:

☐ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: _____

Which is a:

☐ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: _____

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 194 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☒ Cross References to Related Applications *(if applicable)*
 - c. ☐ Statement Regarding Federally-sponsored Research/Development *(if applicable)*
 - d. ☐ Reference to Microfiche Appendix *(if applicable)*
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☐ Brief Description of the Drawings *(if drawings filed)*
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
1073.035A

Total Pages in this Submission

Application Elements (Continued)

3. ☐ Drawing(s) (when necessary as prescribed by 35 USC 113)
- a. ☐ Formal Number of Sheets _____
- b. ☐ Informal Number of Sheets _____
4. ☒ Oath or Declaration
- a. ☐ Newly executed (original or copy) ☒ Unexecuted
- b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- c. ☐ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Computer Program in Microfiche (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
- a. ☐ Paper Copy
- b. ☐ Computer Readable Copy (identical to computer copy)
- c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure Statement/PTO-1449 ☒ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
- ☐ First Class ☒ Express Mail (Specify Label No.): EV 027280406 US

**UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
1073.035A

Total Pages in this Submission

Accompanying Application Parts (Continued)

15. ☐ Certified Copy of Priority Document(s) *(if foreign priority is claimed)*

16. ☒ Additional Enclosures *(please identify below):*

Patent Bibliographic Data Sheet
Communication Accompanying Filing Under 35 USC Section 120

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

17. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
1073.035A


Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED

| For | #Filed | #Allowed | #Extra | Rate | Fee |
|--|--------|----------|--------|-----------|------------|
| Total Claims | 94 | - 20 = | 74 | x \$18.00 | \$1,332.00 |
| Indep. Claims | 8 | - 3 = | 5 | x \$84.00 | \$420.00 |
| Multiple Dependent Claims (check if applicable) <input type="checkbox"/> | | | | | \$0.00 |
| BASIC FEE | | | | | \$740.00 |
| OTHER FEE (specify purpose) _____ | | | | | \$0.00 |
| TOTAL FILING FEE | | | | | \$2,492.00 |

- ☒ A check in the amount of **\$2,492.00** to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **08-1935** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).


Signature

Philip E. Hansen
Reg. No. 32,700

Customer Acct. N.o.:



23405

PATENT TRADEMARK OFFICE

Dated: January **14**, 2002

CC:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: OHLMEYER *et al.*

Atty. Dkt. No.: 1073.035A

Serial No.: UNKNOWN

Continuation of: PCT/US00/19185

International Filing Date: July 14, 2000

Priority Date: July 15, 1999

Title: BRADYKININ B₁ RECEPTOR ANTAGONISTS

Assistant Commissioner for Patents
Washington, D.C. 20231

COMMUNICATION ACCOMPANYING FILING UNDER 35 USC §120

Dear Sir:

This application is a continuation of PCT application PCT/US00/19185 filed July 14, 2000. An International Preliminary Examination Report was transmitted by the IPEA/EP on August 1, 2001, indicating that all of the claims that were examined (i.e. the claims to compounds and compositions) met all of the criteria of PCT Article 34 as to novelty, non-obviousness and utility. The present continuation is identical to the PCT application (with the claims as amended under Article 34) except that the multiple dependencies have been eliminated from the claims and a "Cross-reference to Related Applications" section has been added to the specification.

2001-01-10 10:10:10

OHLMEYER *et al.*

Atty. Docket No.: 1073.035A

Claim 2 from the PCT has been made new claim 28, and the claims that were dependent on it are 29-47, PCT claims 12 and 13 have been combined (into claim 11); PCT claim 28 has been expanded into new 26 and 27 (to eliminate multiple dependency). Similarly, the pharmaceutical composition claims have been split into two groups: 48-58, depending from 1; and 59-69, depending from 28 (formerly 2). Claims 70 to 94 are method claims and were not examined in Chapter II.


Respectfully submitted,



Philip E. Hansen
Agent for Applicants

Dated: January ¹⁴/, 2002

HESLIN ROTHENBERG FARLEY & MESITI P.C.
5 Columbia Circle
Albany, New York 12203
Telephone: (518) 452-5600
Facsimile: (518) 452-5579

| | | | |
|---|-------------|----------|-------------------------|
| CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10) Applicant(s): Ohlmeyer et al. | | | Docket No. 1073.035A |
| Serial No. | Filing Date | Examiner | Group Art Unit |
| Invention: BRADYKININ B1 RECEPTOR ANTAGONISTS | | | |
| I hereby certify that the following correspondence: <div style="border: 1px solid black; padding: 10px; margin: 10px 0;">Patent Application and accompanying documents</div> <p style="text-align: center;"><i>(Identify type of correspondence)</i></p> <p>is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on</p> <p style="text-align: center;"><u>January /4 , 2002</u> <i>(Date)</i></p> <div style="text-align: right; margin-top: 20px;"><p><u>Jill K. Becker</u> <i>(Typed or Printed Name of Person Mailing Correspondence)</i></p><p> <i>(Signature of Person Mailing Correspondence)</i></p><p><u>EV 027280406 US</u> <i>("Express Mail" Mailing Label Number)</i></p></div> | | | |
| Note: Each paper must have its own certificate of mailing. | | | |